Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome

Archives of Dermatology

Volumn 148, Issue 4, 2012, Pages 546-547

  Bos, Willemijn E M ^a   Nijsten, Tamar E C ^a   De Jonge, Maja J A ^a   Hamberg, A P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; METHOXSALEN; PREDNISONE; PSORALEN; SUNITINIB;

ANALGESIA; ARTICLE; BLISTER; BURNING PAIN; CASE REPORT; DESQUAMATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPOMANIA; KIDNEY CANCER; KIDNEY CARCINOMA; NEUROPATHIC PAIN; PAIN; PRIORITY JOURNAL; PUVA; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PUVA THERAPY; PYRIMIDINES; PYRROLES;

EID: 84860008999     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3482     Document Type: Article

References (3)

1. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257-271.
2. US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Institutes of Health; 2010.
3. White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol. 2008;21(5):580-585.